Literature DB >> 3895232

Complement-dependent cellular cytotoxicity: lymphoblastoid lines that activate complement component 3 (C3) and express C3 receptors have increased sensitivity to lymphocyte-mediated lysis in the presence of fresh human serum.

O F Ramos, G Sármay, E Klein, E Yefenof, J Gergely.   

Abstract

Lymphocyte-mediated lysis of cells of the Raji, Daudi, Jijoye, and Bjab lines was elevated when fresh human serum was added to the assay. A higher proportion of effector-target conjugates was observed in the presence of human serum. In similar experiments lysis of 1301, Rael, and P3HR-1 cells was unaltered. All cell lines activated the alternative pathway of complement but they varied in the expression of receptors for complement component 3 (C3) and in the ability to fix the C3 cleavage products on their membrane. The enhancement of lysis in the presence of human serum occurred only with those cells that bound C3. This characteristic was correlated to the expression of C3 receptors. Analysis of the nature of the deposited C3 was performed with Raji cells. Raji cells exposed to human serum bound C3b as indicated by the immunoadherence test. The C3b was further processed to C3bi, because the immunoadherence declined with time and conjugate formation increased with Daudi cells, which carry the C3 receptors CR2 and CR3. This suggests that in the lytic assay lymphocytes with C3bi receptors are recruited in the presence of human serum. We assume that the bridge of C3 molecules between targets and effectors increases the avidity of their interaction.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3895232      PMCID: PMC391144          DOI: 10.1073/pnas.82.16.5470

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  26 in total

1.  Complement receptor distinguishes between two subsets of large granular lymphocytes with different natural killer activity and cytochemical and ultrastructural features.

Authors:  A Nocera; E Montesoro; P Balbo; M Ferrarini; A Leprini; A Zicca; C E Grossi
Journal:  Scand J Immunol       Date:  1983-10       Impact factor: 3.487

2.  Analysis of gp 140, a C3b-binding membrane component present on Raji cells: a comparison with factor H.

Authors:  R Frade; M Barel; L Krikorian; C Charriaut
Journal:  Eur J Immunol       Date:  1984-06       Impact factor: 5.532

3.  C3 receptors on human lymphocyte subsets and recruitment of ADCC effector cells by C3 fragments.

Authors:  B Wåhlin; H Perlmann; P Perlmann; R D Schreiber; H J Müller-Eberhard
Journal:  J Immunol       Date:  1983-06       Impact factor: 5.422

4.  C3b deposition during activation of the alternative complement pathway and the effect of deposition on the activating surface.

Authors:  M K Pangburn; R D Schreiber; H J Müller-Eberhard
Journal:  J Immunol       Date:  1983-10       Impact factor: 5.422

Review 5.  Complement and tumor immunology.

Authors:  K Nishioka
Journal:  Adv Cancer Res       Date:  1971       Impact factor: 6.242

6.  Complement-dependent cellular cytotoxicity due to alternative pathway C3 activation by the target cell membrane.

Authors:  E Yefenof; I Yron; E Klein
Journal:  Cell Immunol       Date:  1984-09       Impact factor: 4.868

7.  Substances that can trigger activation of the alternative pathway of complement have anti-melanoma activity in mice.

Authors:  P D Cooper; R B Sim
Journal:  Int J Cancer       Date:  1984-05-15       Impact factor: 7.396

Review 8.  The human C3b receptor.

Authors:  D T Fearon
Journal:  Springer Semin Immunopathol       Date:  1983

9.  Activation of cytotoxic activity of human blood lymphocytes by tumor-promoting compounds.

Authors:  O F Ramos; M G Masucci; E Klein
Journal:  Cancer Res       Date:  1984-05       Impact factor: 12.701

10.  Identification of the membrane receptor for the complement fragment C3d by means of a monoclonal antibody.

Authors:  K Iida; L Nadler; V Nussenzweig
Journal:  J Exp Med       Date:  1983-10-01       Impact factor: 14.307

View more
  11 in total

1.  CR2-mediated activation of the complement alternative pathway results in formation of membrane attack complexes on human B lymphocytes.

Authors:  C H Nielsen; H V Marquart; W M Prodinger; R G Leslie
Journal:  Immunology       Date:  2001-12       Impact factor: 7.397

2.  Regulation of CR3 (CD11b/CD18)-dependent natural killer (NK) cell cytotoxicity by tumour target cell MHC class I molecules.

Authors:  V Vĕtvicka; M Hanikýrová; J Vĕtvicková; G D Ross
Journal:  Clin Exp Immunol       Date:  1999-02       Impact factor: 4.330

3.  Phenotypic study of CD4+ and CD8+ lymphocyte subsets in relation to cytomegalovirus carrier status and its correlate with pokeweed mitogen-induced B lymphocyte differentiation.

Authors:  J W Gratama; R A Langelaar; M A Oosterveer; J A van der Linden; A den Ouden-Noordermeer; A M Naipal; J W Visser; G C de Gast; H J Tanke
Journal:  Clin Exp Immunol       Date:  1989-08       Impact factor: 4.330

4.  Complement activation by malignant B cells from patients with chronic lymphocytic leukaemia (CLL).

Authors:  H V Marquart; K Grønbaek; B E Christensen; S E Svehag; R G Leslie
Journal:  Clin Exp Immunol       Date:  1995-12       Impact factor: 4.330

5.  Complement activation in Mycoplasma fermentans-induced mycoplasma clearance from infected cells: probing of the organism with monoclonal antibodies against M161Ag.

Authors:  S Kikkawa; M Matsumoto; T Sasaki; M Nishiguchi; K Tanaka; K Toyoshima; T Seya
Journal:  Infect Immun       Date:  2000-03       Impact factor: 3.441

6.  IgG Fc domains that bind C1q but not effector Fcγ receptors delineate the importance of complement-mediated effector functions.

Authors:  Chang-Han Lee; Gabrielle Romain; Wupeng Yan; Makiko Watanabe; Wissam Charab; Biliana Todorova; Jiwon Lee; Kendra Triplett; Moses Donkor; Oana I Lungu; Anja Lux; Nicholas Marshall; Margaret A Lindorfer; Odile Richard-Le Goff; Bianca Balbino; Tae Hyun Kang; Hidetaka Tanno; George Delidakis; Corrine Alford; Ronald P Taylor; Falk Nimmerjahn; Navin Varadarajan; Pierre Bruhns; Yan Jessie Zhang; George Georgiou
Journal:  Nat Immunol       Date:  2017-06-12       Impact factor: 25.606

7.  Biological characterization of a chimeric mouse-human IgM antibody directed against the 17-1A antigen.

Authors:  W E Fogler; L K Sun; M R Klinger; J Ghrayeb; P E Daddona
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

8.  The requirement of localized, CR2-mediated, alternative pathway activation of complement for covalent deposition of C3 fragments on normal B cells.

Authors:  E H Olesen; A A Johnson; G Damgaard; R G Leslie
Journal:  Immunology       Date:  1998-02       Impact factor: 7.397

9.  Cell-surface bound complement regulatory activity is necessary for the in vivo survival of KDH-8 rat hepatoma.

Authors:  L Baranyi; K Baranji; H Takizawa; N Okada; H Okada
Journal:  Immunology       Date:  1994-08       Impact factor: 7.397

10.  Receptors for the third component of complement: their association with maturation stage in non-Hodgkin lymphomas (NHL) and their possible implication with the development of follicular structures.

Authors:  R Greil; C Gattringer; T Schulz; W Knapp; T Radaskiewicz; M P Dierich; H Huber
Journal:  Clin Exp Immunol       Date:  1986-05       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.